{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-110484","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2025-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.355282+00:00","generated_at":"2026-05-17T11:04:16.627106+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Alaunos regains Nasdaq compliance after reporting $3.66M equity in Q2 2025","bullets":["Nasdaq notified Alaunos of compliance on August 19, 2025, following prior stockholders' equity deficiency.","Company had reported $2.06M equity in 2024 10-K, below $2.5M minimum for continued listing.","Q2 2025 10-Q showed $3.66M equity, meeting Nasdaq's requirement; compliance plan submitted earlier.","Matter closed; no immediate delisting risk."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-110484","json":"https://secwatch.observer/filing/0000950170-25-110484.json","markdown":"https://secwatch.observer/filing/0000950170-25-110484.md","text":"https://secwatch.observer/filing/0000950170-25-110484.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000095017025110484/0000950170-25-110484-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000095017025110484/tcrt-20250819.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:04:16.627106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}